Clinical Trial Update: A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing risankizumab to placebo in active psoriatic arthritis, including patients with prior inadequate response or intolerance to biologic th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis (PsA) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-02